Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, Endometrioid endometrial carcinoma, Primary cell cultures, Metformin, In vivo, CELL-LINES, CANCER, DRUG, MECHANISMS, MUTATION, NSCLC, Animals, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Endometrioid, Endometrial Neoplasms, Female, Humans, Mice, Mice, Nude, Xenograft Model Antitumor Assays, 1112 Oncology and Carcinogenesis, 1114 Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis, 3215 Reproductive medicine

Abstract:

New treatment options for advanced and recurrent endometrial carcinoma (EC) are necessary. Epidemiological studies showed that diabetic patients using metformin have reduced risks of endometrial cancer (EC) incidence. Moreover, pre- and clinical studies demonstrated an antitumor effect by metformin, with and without additional treatments, for different solid malignancies. However, cancer cell-autonomous effects of metformin on EC have not been fully characterized yet. The aim of this study was to investigate the effect of metformin, with or without carboplatin, on patient-derived primary endometrioid EC cells xenografted in nude mice, to assess its ability to reduce or impair growth in already established tumors.